{"id":389095,"date":"2023-12-26T00:00:00","date_gmt":"2023-12-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0006-2023-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-forecast-g7-2023\/"},"modified":"2026-03-31T10:31:22","modified_gmt":"2026-03-31T10:31:22","slug":"dlsfon0006-2023-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0006-2023-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin\u2019s lymphoma (NHL) \/ chronic lymphocytic leukemia (CLL) therapy market. Key therapies that we expect to fuel growth are the CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), Tecartus (Gilead), and Breyanzi (Bristol Myers Squibb) as well as the targeted agents Polivy (Roche), Monjuvi \/ Minjuvi (MorphoSys \/ Incyte), Tazverik (Epizyme), Brukinsa (BeiGene), and Zynlonta (ADC Therapeutics); also, approval of bispecific antibodies Lunsumio (Roche), Epkinly \/ Tepkinly (Genmab \/ AbbVie), and Columvi (Roche) will drive growth. We also expect the noncovalent BTK inhibitor Jaypirca (Loxo Oncology \/ Eli Lilly) for CLL \/ SLL and combinations incorporating Imbruvica (Janssen \/ AbbVie), Calquence (AstraZeneca), and Venclexta \/ Venclyxto (AbbVie \/ Roche) to enter the CLL market, causing a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of other bispecific antibody\u2014odronextamab (Regeneron Pharmaceuticals), antibody-drug conjugate brentuximab vedotin (Seagen) etc. will further fragment the FL, CLL \/ SLL, DLBCL, and MCL patient settings, creating intense competition.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What is the size of clinically and commercially relevant drug-treatable NHL \/ CLL populations, and how will drug-treatment rates change over the 2022-2032 forecast period, by geography?<\/li>\n<li>What is the market impact of label expansions of CAR T-cell therapies in earlier lines of R\/R DLBCL? What is the expected market impact of other drug approvals in various NHL \/ CLL\u00a0patient populations?<\/li>\n<li>Which emerging therapies are the most promising in NHL \/ CLL, and what patient populations will they target?<\/li>\n<li>What factors are driving growth in the NHL \/ CLL market? Which drug class will dominate the treatment of NHL \/ CLL?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<p>Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p>Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.<\/p>\n<p>Epidemiology: Diagnosed incidence of NHL by country; drug-treatable and drug-treated cases segmented by subtype (follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia \/ small lymphocytic leukemia) and line of therapy.<\/p>\n<p>Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL \/ SLL, DLBCL, and MCL.<\/p>\n<p>Emerging therapies: Phase III \/ PR: 4+ drugs.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n<p>Additionally, Disease Landscape &#038; Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389095","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389095\/revisions"}],"predecessor-version":[{"id":576000,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389095\/revisions\/576000"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}